Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the . | Cost Effectiveness and Resource Allocation BioMed Central Open Access Research Health and economic impact of combining metformin with nateglinide to achieve glycemic control Comparison of the lifetime costs of complications in the Alexandra J Ward 1 Maribel Salas1 J Jaime Caro1 2 and David Owens3 Address 1Caro Research Institute Concord MA USA 2Division of General Internal Medicine McGill University Montreal Quebec Canada and 3Diabetes Research Unit Llandough Hospital Penarth UK Email Alexandra J Ward - alexward@ Maribel Salas - msalas@ J Jaime Caro - jcaro@ David Owens - Owensdr@ Corresponding author Published 15 April 2004 Received 09 June 2003 Cost Effectiveness and Resource Allocation 2004 2 2 Accepted 15 April 2004 This article is available from http content 2 1 2 2004 Ward et al licensee BioMed Central Ltd. This is an Open Access article verbatim copying and redistribution of this article are permitted in all media for any purpose provided this notice is preserved along with the article s original URL. Abstract Background To reduce the likelihood of complications in persons with type 2 diabetes it is critical to control hyperglycaemia. Monotherapy with metformin or insulin secretagogues may fail to sustain control after an initial reduction in glycemic levels. Thus combining metformin with other agents is frequently necessary. These analyses model the potential long-term economic and health impact of using combination therapy to improve glycemic control. Methods An existing model that simulates the long-term course of type 2 diabetes in relation to glycosylated haemoglobin HbA1c and post-prandial glucose PPG was used to compare the combination of nateglinide with metformin to monotherapy with metformin. Complication rates were estimated for major diabetes-related complications macrovascular and microvascular based on existing epidemiologic studies and clinical trial .
